Table 1.

Clinicopathological Characteristics of Patients

Patient Number	Age (year)	Gender	Histologic Tumor Subtype	Tumor Grade	Pre-therapy Size (cm)	Chemotherapy Regimen	NP (%)	Pathological Response
1	55	Male	Myxoid Liposarcoma	Inter	13.5	IE + S	95	Optimal
2	60	Female	Myxoid Liposarcoma	Inter	13.1	IE + S	85	Suboptimal
3	62	Female	Myxofibrosarcoma	Inter	20.6	IE	50	Suboptimal
4	38	Male	Pleomorphic/Undifferentiated/Spindle	Inter	22.5	IE + S	95	Optimal
5	58	Male	Myxoid Liposarcoma	Inter	24.6	IE + S	95	Optimal
6	43	Male	Spindle Cell Sarcoma	Inter	6.4	IE + S	30	Suboptimal
7	58	Male	Pleomorphic/Undifferentiated/Spindle	High	7.3	IE + S	99	Optimal
8	53	Male	Synovial Sarcoma	Inter	12.7	IE + S	60	Suboptimal
9	25	Male	Synovial Sarcoma	Inter	10.9	IE + S	80	Suboptimal
10	40	Female	Pleomorphic Liposarcoma	High	15.9	IE	80	Suboptimal
11	53	Male	Pleomorphic/Undifferentiated/Spindle	High	5.0	IE	99	Optimal
12	26	Male	Myxofibrosarcoma	Inter	10.4	IE	99	Optimal
13	64	Male	Pleomorphic/Undifferentiated/Spindle	High	8.6	IE	98	Optimal
14	33	Male	Synovial Sarcoma	High	8.0	IE	70	Suboptimal
15	57	Male	Pleomorphic/Undifferentiated/Spindle	Inter	9.0	IE	99	Optimal
16	34	Male	Myxoid Liposarcoma	Inter	5.6	IE	90	Suboptimal
17	64	Female	Pleomorphic/Undifferentiated/Spindle	High	5.7	IE	98	Optimal
18	69	Male	Pleomorphic/Undifferentiated/Spindle	High	18.8	IE	90	Suboptimal
19	40	Female	Myxofibrosarcoma	Inter	6.6	IE	5	Suboptimal
20	46	Male	Synovial Sarcoma	Inter	12.8	IE	30	Suboptimal

Abbreviations: NP, necrosis percentage; Inter, intermediate; IE, Ifosfamide + Epirubicin; S, Sorafenib.

Pre-therapy tumor size was the longest diameter (LD) measured from post-contrast DCE-MRI images.